|
 |
FabrazymeThis page contains recent news articles, when available, and an overview of Fabrazyme but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.In addition, Genzyme also provided an update on the resumption of supply of Fabrazyme, indicated for Fabry disease, which was also affected by the temporary ... Zacks.com World stock markets news summary (US, UK, Europe, Asia) (January 05, 2010) - 05 Jan 2010 ...(RTRS) Genzyme/Hospira – Cos. ion pact related to Cerezyme/ Fabrazyme and others. (BBG) Deutsche Bank – Co.'s employees should be spared having to absorb ... Stock Markets Review Drug stocks gain; Athersys soars for second day - Dec 22, 2009 The FDA has allowed Replagel to be supplied to certain patients in the US because of on-going shortage of Fabrazyme due to manufacturing problems at a key ... MarketWatch Shire seeks approval to treat Fabry disease - Dec 22, 2009 Replagal, currently available to Fabry disease patients in the United States under an FDA-approved treatment protocol, would compete with Fabrazyme, ... Boston Globe Genzyme Sends Letter To Reassure Shareholders - Dec 10, 2009 Meanwhile, a viral contamination at the plant caused a temporary shutdown in June, leading to ongoing shortages of Cerezyme and Fabrazyme, and damaging ... Wall Street Journal STOCKS NEWS EUROPE-Shire down; UBS cuts to "neutral" - Dec 17, 2009 O) fail to fully resume production of its enzyme replacement therapy, Fabrazyme production in 2010. And the broker sees around 17 pence potential upside to ... Reuters UK Genzyme Lab Recognized for Quality. Yes, Really. - Dec 13, 2009 The contamination issues have led to shortages of Gaucher's disease drug Cerezyme (imiglucerase) and Fabry disease drug Fabrazyme (agalsidase beta), ... BNET Homebuilders lifted by broker upgrade; FTSE 100 up - Dec 22, 2009 ...s (NASDAQ:GENZ) top-selling product, Fabrazyme. Other drugmakers on the move included AstraZenenca (LSE:UK:AZN) (NYSE:AZN) , up 1.8%, and GlaxoSmithKline ... MarketWatch Guru Stocks at 52-Week Low: Genzyme Corp, Huaneng Power International Inc ... - Jan 2, 2010 Results reflect the impact of the temporary interruption in production of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) associated ... GuruFocus.com Drug companies take medicine - Dec 26, 2009 The plant's ensuing shutdown triggered a global shortage of Genzyme's drugs Cerezyme and Fabrazyme, and created a wide opening for the company's competitors ... Boston Herald Shire Seeks FDA Approval - Dec 28, 2009 ...s (GENZ - Analyst Report) Fabrazyme, arising out of the manufacturing problems at a key Genzyme facility has prompted the FDA to allow Replagel to be ... Zacks.com Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs - Dec 17, 2009 Prior to joining the Company, she served as Vice President of Marketing, Endocrinology at EMD Serono and Senior Director, Global Marketing for Fabrazyme at ... PR Newswire (press release) Shire Making Lemonade with Genzyme's Lemons - Dec 14, 2009 Genzyme (NASDAQ: GENZ) has dominated these two markets for years with its Fabry drug, agalsidase beta (Fabrazyme), and its Gaucher's treatment, ... Xconomy Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market ... - Dec 15, 2009 Product Base and Orphan Drug Status Strengthens Company's positioning 11.2.1.2 Cerezyme 11.2.1.3 Fabrazyme 11.2.2 Celgene Corporation 11.2.2.1 Strengths ... IT News Online Nouveau retard pour l'approvisionnement en Fabrazyme - Dec 9, 2009 Première explication de ce report pour le Fabrazyme®, la productivité cellulaire depuis la reprise en activité des bioréacteurs, à Allston, en août ne s'est ... Vaincre les Maladies Lysosomales Protalix 任命Sandra Lauterbach 為銷售與商æ¥äº‹å‹™éƒ¨å‰¯ç¸½è£? - Dec 17, 2009 ...åœ¨åŠ ç›ŸProtalix 之å‰?，她擔任é?ŽEMD Serono 內分泌å¸è¡ŒéŠ·éƒ¨å‰¯ç¸½è£?å’ŒGenzyme Corporation çš„Fabrazyme å…¨ç?ƒè¡ŒéŠ·éƒ¨é«˜ç´šç¸½ç›£ã€‚ Protalix 總è£?兼行政總è£?David Aviezer å?šå£« ... 財華網 石油è?¯ä¸šè‚¡é¢†æ¶¨ 英股高收0.65% - Dec 22, 2009 ...如果获得许å?¯ï¼ŒReplagal将与Genzyme Corp(GENZ)的畅销产å“?之一Fabrazyme展开竞争。今天高收的制è?¯è‚¡è¿˜æœ‰ï¼šé˜¿æ–¯åˆ©åº·(AZN)的股票上涨1.8%ï¼Œè‘›å…°ç´ -å?²å…‹(GSK)高收1.9%。 ... 证券之星 More contamination troubles for Genzyme - 14 Nov 2009 About 5500 people worldwide, for example, depend on Ce rezyme, the best-selling Genzyme drug, while about 2500 use Fabrazyme. ... Boston Globe FDA finds bits of steel, rubber in Genzyme drugs - 14 Nov 2009 The drugs affected by the latest announcement include: Cerezyme, Fabrazyme, Myozyme, Aldurazyme and Thyrogen. All are manufactured at a biotech plant in ... Chicago Sun-Times National business briefs - 14 Nov 2009 The drugs, which are used to treat rare enzyme disorders, include: Cerezyme, Fabrazyme, Myozyme, Aldurazyme and Thyrogen. ... NewsOK.com Vials of 5 Genzyme Drugs for Rare Diseases May Be Contaminated, F.D.A. Says - 14 Nov 2009 The drugs affected by the FDA's notice on Friday were Cerezyme for the treatment of Gaucher disease; Fabrazyme for Fabry disease; Myozyme for Pompe disease; ... BlueRidgeNow.com Genzyme 3Q profit plunges on facility costs - Oct 21, 2009 Sales of Fabrazyme fell 8 percent to $115.2 million. That drug treats an inherited disorder known as Fabry disease, which is caused by the buildup of a ... The Associated Press Genzyme Corporation - SWOT Analysis - New Report Published - Nov 12, 2009 The increase was primarily due to higher sales of Cerezyme ((imiglucerase for injection), Fabrazyme (agalsidase beta), Renagel (sevelamer hydrochloride), ... OfficialWire (press release) UPDATE 1-U.S. FDA: Some Genzyme drugs contaminated - Nov 13, 2009 The FDA said the affected products included Cerezyme for Gaucher disease, Fabrazyme for Fabry disease, Myozyme for Pompe disease, Aldurazyme for ... 路透中国 FDA Said Pieces Of Steel, Rubber, Fiber Found In Drugs Made By Genzyme (GENZ) - Nov 13, 2009 The drugs include Cerezyme, Fabrazyme, Myozyme, Aldurazyme, and Thyrogen. The FDA estimated that contamination only affected about 1% of the company's ... Comtex Smartrend Genzyme slides on outlook; Antigenics plunges 40% - Oct 21, 2009 Genzyme added that it has resumed production of its top-selling products Cerezyme and Fabrazyme at the re-mediated plant. It expects to begin shipping ... MarketWatch Genzyme Corporation Q3 2009 Earnings Call Transcript - Oct 21, 2009 But the dominant factors clearly are the Allston production and restart of the plant and supply of Cerezyme, Fabrazyme and Myozyme or Lumizyme for that ... Seeking Alpha (blog) Genzyme plant gets OK from European regulators - Nov 3, 2009 Shortages of the two primary drugs made at the plant, Fabrazyme for Fabry disease and Cerezyme for Gaucher disease, have remained a problem since the ... Bizjournals.com Rising market tide fails to lift some Mass. firms - Nov 12, 2009 Genzyme expects to begin shipping the two drugs, Cerezyme and Fabrazyme, at the end of this month and in December, a spokesman said yesterday. ... Boston Globe FDA finds bits of steel, rubber in Genzyme drugs - Nov 13, 2009 The contaminated products, used to treat “rare, serious and life-threatening diseases,â€? are marketed as Cerezyme, Fabrazyme, Myozyme, Aldurazyme and ... Boston Herald Genzyme production in 'recovery mode' - Oct 22, 2009 The Framingham unit will boost Genzyme's capacity to make Fabrazyme while the Belgian plant is intended to manufacture Lumizyme (alglucosidase alfa), ... Pharmafocus Amicus Therapeutics Announces Third Quarter 2009 Financial Results and ... - Oct 29, 2009 A separate Phase 3 study for registration in the European Union comparing Amigal with Fabrazyme® is required by the European Medicines Agency (EMEA). ... Reuters GMP deviators keep paying - Nov 4, 2009 The company has since resumed operations at the plant, which is used to make Cerezyme and Fabrazyme. It says it expects to begin shipping both before year's ... FiercePharma Manufacturing FDA OKs Shire's Replagal treatment protocol; BLA filing soon - Oct 22, 2009 ...disease agent Replagal, giving patients with the rare disorder early access to the drug to help fill the void left by shortages of Genzyme's Fabrazyme. ... Pharma Times FDA finds bits of steel, rubber in Genzyme drugs - Nov 13, 2009 The drugs, which are used to treat rare enzyme disorders, include: Cerezyme, Fabrazyme, Myozyme, Aldurazyme and Thyrogen. ... Metro Canada - Ottawa Genzyme Releases 3Q Financial Results - Oct 26, 2009 These expenses, along with lost Cerezyme/Fabrazyme revenue and a shift in product mix, reduced the gross margin to approximately 67 percent of revenue ... Trading Markets (press release) US stocks advance - Nov 13, 2009 US regulators said some lots of the company's Cerezyme, Fabrazyme, Myozyme, Aldurazyme, and Thyrogen may be contaminated with stainless steel fragments, ... The Age Shire Subpoenaed In US Drug Marketing Probe - Oct 30, 2009 Supplies of Fabrazyme, Genzyme's drug for Fabry disease, have also been affected by its production woes. At 1401 GMT, shares in Shire were up 48 pence, ... Wall Street Journal Plant shutdown weighs on Genzyme earnings - Oct 21, 2009 Genzyme added that it has resumed production of its products Cerezyme and Fabrazyme at the remediated plant. It expects to begin shipping Cerezyme in late ... MarketWatch Genzyme: Focusing on Lumizyme Approval - Oct 30, 2009 ...the company's Allston manufacturing plant, which is where its blockbuster Gaucher disease drug Cerezyme and Fabry disease drug Fabrazyme are produced. ... Seeking Alpha (blog) חדשות טובות עבור פרוטליקס? חשש ×›×™ תרופות של חברת ×’'× ×–×™×™×? זוהמו במתכת וגומי - Nov 13, 2009 ...בחודש ×™×•× ×™ הודיעה ×’'× ×–×™×™×? על השבתת הייצור של שתיי×? מתרופותיה ×”× ×ž×›×¨×•×ª ביותר - Cerezyme ו-Fabrazyme - עקב זיהו×? במפעל של החברה בבוסטון. ... The Marker Allergan Q3 Profit Rises; Lifts FY09 Adj. EPS Outlook - Update - Oct 29, 2009 ...manufacturing facility in Boston that resulted in restricted supplies of the company's Gaucher disease drug Cerezyme and Fabry disease drug Fabrazyme. ... Trading Markets (press release) Genzyme 盈馀低於预期，股价下跌4% - Oct 21, 2009 ...第三å£Cerezymeè?¯å“?销售é¢?为9360万美元，市场预期1.01忆美元；Renagel销售é¢?1.817忆美元，市场预期1.8忆美元；Fabrazyme销售é¢?1.152忆美元，市场预期1.14亿 ... 凤凰网 Genzyme下调2009财年盈馀预期 - Oct 21, 2009 Genzyme还表示，已在修å¤?後的工厂æ?¢å¤?Cerezymeå’ŒFabrazyme的生产，并预计这两款产å“?将分别於11月底和12月底开始出货。 å…?责声明：本文仅代表作者个人观点，与凤凰网 ... 凤凰网 Genzyme下調2009財年盈餘é ?期 - Oct 21, 2009 ...盈餘約2.26美元，低於先å‰?é ?期的2.35-2.90美元。 Genzymeé‚„è¡¨ç¤ºï¼Œå·²åœ¨ä¿®å¾©å¾Œçš„å·¥å» æ?¢å¾©Cerezymeå’ŒFabrazyme的生產，並é ?計這兩款產å“?將分別於11月底和12月底開始出貨。 鉅亨網 Genzyme: Πτώση κεÏ?δών και εσόδων το γ΄ Ï„Ï?ίμηνο - Oct 21, 2009 η πτώση των κεÏ?δών οφείλεται κατά κÏ?Ï?ιο λόγω στο Ï€Ï?οσωÏ?ινό κλείσιμο του εÏ?γοστασίου που παÏ?ήγαγε τα σημαντικότεÏ?α σκευάσματα Cerezyme και Fabrazyme. Capital.gr 세계 ì œë„¤ë¦ì‚¬ ë°”ì?´ì˜¤ì‹œë°€ëŸ¬ 개발 활발 - Oct 20, 2009 ...ì„¸ë ˆìž?ìž„'(Cerezyme, imiglucerase), 'ì‹ ë¹„ìŠ¤í?¬'(Synvisc, hylan GF 20), '파브ë?¼ìž?ìž„'(Fabrazyme, agalsidase beta) 등ì?˜ 특허가 모ë‘? 만료ë? ì „ë§?ì?´ë‹¤. 디지틀보사 Genzyme's Near-Term Growth Seen Driven By Renagel - Apr 20, 2006 ..."According to Genzyme, many of the Fabrazyme patients began treatment toward the end of the quarter and the impact of this and continued patient accrual ... Forbes Genzyme Beats, Holds to Lowered Guidance - Jul 23, 2008 However, sales of the company's lysosomal storage disorder drugs, Cerezyme, Fabrazyme and Myozyme all came in above expectations. ... TheStreet.com - TheStreet.com (subscription) Genzyme stock leaps as profit tops forecast. - Jul 13, 2006 Sales of Fabrazyme, a similar treatment for a rare genetic disorder called Fabry disease, rose 20 percent last quarter to $89 million. ... Free with registration - Boston Globe - AccessMyLibrary.com Genzyme profits leap 58 percent in second quarter. - Jul 15, 2005 Strong sales of the drug Fabrazyme, used to treat a rare genetic disorder, and Synvisc, ... Fabrazyme, introduced in Europe in 2001 and in the US in 2003, ... Free with registration - Boston Globe - AccessMyLibrary.com Genzyme 3rd-quarter earnings beat expectations - Oct 24, 2007 Sales of Fabrazyme, for the treatment of the genetic disorder Fabry disease, rose 12 percent to $104.6 million while sales of Cerezyme, for Gaucher disease, ... Reuters Genzyme seeks OK for Pompe disease drug.(Myozyme) - Jul 30, 2005 It would join Cerezyme, which has 4400 patients, and a newer drug called Fabrazyme, with about 1500. Genzyme also sells a similar drug, Aldurazyme, ... Free with registration - Boston Globe - AccessMyLibrary.com … -Ever Fabry Study Shows Earlier Treatment With Fabrazyme(R) 1mg/Kg ... - Jan 16, 2007 TORONTO, ON, CANADA -- January 16, 2007 -- The largest-ever placebo-controlled study of the ultra-rare Fabry disease appears in the January 16th edition of ... DG News Genzyme's Revenue Set to Climb - Jan 9, 2006 The kidney disease drug Renagel saw a 12% increase in sales to $111 million, while the Fabry disease treatment Fabrazyme had a sales increase of 27% to $81 ... TheStreet.com - TheStreet.com (subscription) Genzyme seeks to treat Fabry disease earlier - Oct 15, 2008 As many as 20 institutions in the United States, Canada, Latin America and Europe will take part in the study, which will look at Fabrazyme in low doses in ... Bizjournals.com Genzyme's revenue up 17 percent in quarter - Jan 9, 2007 Fourth quarter sales of Fabrazyme for Fabry disease were $96 million, up 18 percent from $82 million last year. The company said full-year sales of the drug ... Boston Globe Q3 2006 Genzyme Corporation Earnings Conference Call - Final. - Oct 12, 2006 It's off on a stronger start than what we have experienced around Aldurazyme or Fabrazyme in the near past, and we think it's going to be a very significant ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Patients await approval of Fabry disease therapy - Feb 9, 2005 The treatment at issue is an enzyme replacement therapy called Fabrazyme. ... [Paul Drohan] said governments in 40 countries pay for Fabrazyme. ... Pay-Per-View - The Record - ProQuest Archiver Fabry disease sufferers to rally in Toronto - Jun 2, 2005 He said Fabrazyme had relieved his stomach and extremity pain and fatigue. But a panel of experts which advised the Common Drug Review, said there was no ... Pay-Per-View - The Record - ProQuest Archiver Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude … - Jan 9, 2007 For the year, Fabrazyme sales grew 18 percent to $359 million, ... Results from the Phase 4 clinical trial of Fabrazyme were published last month in Annals ... webwire.com Family anger at 'health lottery' - Oct 12, 2005 In a statement, the commission said: "Fabrazyme is a high cost drug ... It said all new Fabrazyme cases would be assessed by a group set up to advise it on ... BBC News Отчет Genzyme за I квартал 2007 г. - Apr 27, 2007 Объем продаж компании выроÑ? на 21% и Ñ?оÑ?тавил 883,2 млн долл. СШÐ?. Ðтому Ñ?поÑ?обÑ?твовало увеличение объемов продаж препаратов Cerezyme, Fabrazyme и Renagel. ФармацевтичеÑ?кий веÑ?тник Moniteur Belge - Belgisch Staatsblad - Jun 10, 2006 35° de geneesmiddelen Fabrazyme, Replagal, Tracleer en Aldurazyme, onder de voorwaarden die respectievelijk vastgesteld zijn door de paragrafen 297, 298, ... Belgisch Staatsblad New Genzyme fight fails to overshadow TKT comeback. - Jan 31, 2005 Genzyme had Fabrazyme (agalsidase beta) and TKT had Replagal (agalsidase alfa). ... Fabrazyme, he noted, has been gaining ground for some time in Europe. ... Free with registration - Bioworld Financial Watch - AccessMyLibrary.com Salute e Benessere Cybermed - Il Portale Europeo di informazione … - May 29, 2008 Fabrazyme nel 2001 è stata la prima terapia al mondo a ottenere ... Fabrazyme è stato approvato nei paesi dell'Unione Europea nel 2001 dopo il completamento ... cybermed.it Witmer slams province for not helping Fabry's sufferers - Jun 27, 2005 ...speed up approval of Herceptin for cancer patients, he should also try to speed up approval of Fabrazyme, which costs $300000 a year for each patient. ... Pay-Per-View - The Record - ProQuest Archiver Genzyme Reports Financial Results for Fourth Quarter of 2006 and Full... - Feb 14, 2007 Results from the Phase 4 trial of Fabrazyme were published in December in ... The trial showed that Fabrazyme reduced the risk of major clinical events that ... webwire.com Transkaryotic Therapies neutral - May 6, 2005 Die Umsatzentwicklung deute nach Einschätzung der Analysten darauf hin, dass der Wettbewerber Genzyme mit dem Medikament "Fabrazyme" weiterhin die führende ... AktienCheck Event Brief of Q1 2006 Genzyme Corporation Earnings Conference Call -... - Apr 19, 2006 The timing of the patient accruals for Fabrazyme. 2. ... Fabrazyme revenue was $81m and represented about 15% YtoY increase. 4. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Des protéines pour traiter des maladies graves - Aug 21, 2007 Fabrazyme et Replagal ont changé la vie de malades à l'espérance de vie précédemment limitée. C'est dans ce type de bioréacteurs qu'est produite Fabrazyme, ... Les Échos - Les Échos FDA finds steel, rubber, other substances in Genzyme biotech drugs, … - May 28, 2008 Its second-best seller Fabrazyme treats an inherited disorder known as Fabry disease, which is caused by the buildup of a particular type of fat in the ... Los Angeles Times Rare diseases, pricey drugs and unanswered questions - Jan 30, 2007 ..."It was clear that based on our criteria, even before the review, Fabrazyme would not meet standards of cost-effectiveness," he said. ... National Review of Medicine Governments plan three-year Fabry drug study - Jun 15, 2006 The only two therapies -- Fabrazyme, made by Genzyme Canada, and Replagal, developed by Shire Human Genetic Therapies -- cost on the order of $250000 to ... Pay-Per-View - The Record - ProQuest Archiver Widow cheers funds to fight Fabry - May 16, 2006 Two existing enzyme replacement therapies, Fabrazyme and Replagal, which cost an average $250000 a year, will be funded for three years if patients ... Pay-Per-View - The Record - ProQuest Archiver Genzyme Delivers Excellent Fourth-Quarter and 2004 Performance ------... - Feb 17, 2005 Fabrazyme sales have grown significantly since the product was first introduced ... Genzyme anticipates that Fabrazyme will continue to gain market share in ... $4.95 - PR Newswire - ECNext Genzyme: Geared for Growth - Jun 11, 2007 Other marketed ERT products include Fabrazyme, which was approved in the US and Europe for ... Fabrazyme sales were $359 million in 2006, up 18% over 2005. ... BusinessWeek Genzyme Reports Financial Results for Fourth Quarter of 2005 and Full... - Feb 15, 2006 Sales of Fabrazyme® (agalsidase beta) are expected to reach $370-$390 million this year, compared with $305 million in 2005. ... webwire.com Genzyme Reports Financial Results for Fourth Quarter of 2005 and Full... - Feb 15, 2006 Sales of Fabrazyme(R) (agalsidase beta) are expected to reach $370-$390 million this year, compared with $305 million in 2005. ... $4.95 - PR Newswire - ECNext Q1 2005 Genzyme Corporation Earnings Conference Call - Final. - Apr 21, 2005 Fabrazyme revenue was on target with $70 million with continued growth that we're seeing ... Our European Fabrazyme revenue increased to about $30 million. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue - Jan 9, 2006 Fourth-quarter sales of Fabrazyme® (agalsidase beta) enzyme replacement therapy for Fabry ... For the year, Fabrazyme sales grew 45 percent to $305 million, ... webwire.com Genzyme Profits Leap 58 Percent in Second Quarter - Jul 14, 2005 Strong sales of the drug Fabrazyme, used to treat a rare genetic disorder, and Synvisc, ... Fabrazyme, introduced in Europe in 2001 and in the US in 2003, ... RedOrbit Genzyme Profit Rises on Genetic-Disease Medicines - Oct 24, 2007 The medicines include Fabrazyme for Fabry disease and Aldurazyme for a ... Sales of Fabrazyme, for Fabry disease, climbed 12 percent to $104.6 million. ... Bloomberg Genzyme 3rd-Quarter Profit Drops 86% on Acquisitions - Oct 12, 2006 Sales of Fabrazyme rose to $93.2 million from $79.1 million. Revenue from Aldurazyme increased to $25 million from $20.1 million. ... Bloomberg Genzyme Reports Second-Quarter GAAP EPS of $0.46, Non-GAAP EPS … - Jul 14, 2005 Within the Therapeutics area, sales of Fabrazyme(R) (agalsidase beta) enzyme replacement therapy for Fabry disease rose 50 percent to $74.4 million from ... $4.95 - PR Newswire - ECNext Maladie de Fabry: Comparaison des traitements enzymatiques - Sep 4, 2007 Deux équipes de chercheurs ont comparé l'efficacité des deux médicaments actuellement prescrits dans la maladie de Fabry: le Replagal® et le Fabrazyme®. ... Association Vaincre les Maladies... Genzyme Corp - Jun 19, 2006 ...tial for Myozyme is between that of Fabrazyme. and Cerezyme. ... Enzyme replacement therapy Fabrazyme was approved in Europe in August 2001 and in the U.S. ... $35.00 - Stock Reports - Standard & Poor's A new hope for Valley family with genetic disease ** For years, her... - Aug 21, 2005 An estimated 570 Americans are taking Fabrazyme, including 23 from Pennsylvania, Genzyme representative William Cook said. Seventy- two percent are men. ... Pay-Per-View - Morning Call - ProQuest Archiver Genzyme Reports Strong Fourth-Quarter Revenue Growth. - Jan 11, 2005 Sales of Fabrazyme(R) (agalsidase beta) doubled in the fourth quarter, rising to $64 million from $32 million in the same quarter a year ago. ... $4.95 - PR Newswire - ECNext Genzyme; Recent developments from Genzyme summarized - Dec 12, 2006 Fabrazyme growth will be driven by the continued accrual of new patients on therapy, ... Within the Therapeutics area, sales of Fabrazyme enzyme replacement ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Research and Markets: Benchmark Genzymes Performance against Key … - Dec 15, 2006 Fabrazyme Hectorol Therapy area analysis, 2005-11 Other Hematology ... Fabrazyme Overview Sales forecast Newsflow Competitive landscape Myozyme Overview ... $4.95 - Business Wire - ECNext Genzyme 3rd-qtr sales rise; profit falls on charge - Oct 22, 2008 Sales of Fabrazyme, a treatment for the genetic disorder Fabry disease, which rose 20 percent to $125.6 million. Sales of Cerezyme, for Gaucher disease, ... Reuters Provinces, Ottawa agree to drug therapy for rare illness - May 13, 2006 Although Health Canada has licensed two drugs to treat the condition — Fabrazyme and Replagal — provinces have struggled to pay for them. ... Globe and Mail Genzyme Beats Earnings Targets - Apr 23, 2008 Sales of injected Gaucher disease drug Cerezyme rose 15% to $304 million and sales of Fabry disease treatment Fabrazyme increased 16% to $117 million year ... TheStreet.com - TheStreet.com (subscription) Genzyme Corporation Analyst Meeting - Final. - May 6, 2005 We added Fabrazyme, we added biosurgery, we added transplant, we added IMPATH, ... We also had under development Fabrazyme, but they weren't there yet. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com SIMPOSIUM INTERNACIONAL SOBRE LAS ENFERMEDADES DE … - Mar 30, 2005 Más recientemente, Genzyme introdujo Fabrazyme® para la enfermedad de Fabry, y Aldurazyme® para la Mucopolisacaridosis Tipo I, y la experiencia acumulada ... acceso.com Event Brief of Q2 2007 Genzyme Corporation Earnings Conference Call -... - Jul 25, 2007 Rounding out the LSD area, Fabrazyme increased to $104m or. outside the US. 1. Currently treatment on Fabrazyme is about 2000 patients worldwide. 5. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Genzyme Meets Views, Sees Strong Revenue - Feb 13, 2008 Fabry disease treatment Fabrazyme and Pompe disease treatment Myozyme generated sales of $114 million and $62 million, respectively. ... TheStreet.com - TheStreet.com (subscription) Genzyme quarterly revenue slightly beats forecast - Jan 8, 2008 Sales of Fabrazyme, a treatment for Fabry disease, rose 18 percent to $114 million. Quarterly sales of Aldurazyme, an enzyme replacement therapy for a ... Reuters Biotech Preview: Genzyme, Biogen, Amgen, Celgene - Jan 14, 2008 Coming in at the top end of estimates, Fabry disease treatment Fabrazyme and Pompe disease treatment Myozyme generated sales of $114 million and $62 million ... TheStreet.com - TheStreet.com (subscription) Event Brief of Q3 2005 Genzyme Corporation Earnings Conference Call -... - Oct 18, 2005 While the revenue increases in Renagel, Synvisc, Fabrazyme continues to be the key drivers, breaking it away, all of GENZ's products increased on a qtr. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Q2 2006 Genzyme Corporation Earnings Conference Call - Final. - Jul 12, 2006 Fabrazyme was up 9 million or 11% from the first quarter. Clearly back on track. We will have [through Q&A] published questions around Fabrazyme. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Genzyme is upbeat on Myozyme data - May 2, 2005 Sales of Fabrazyme soared 84 percent to $70 million in the first quarter, while Cerezyme brought in $220 million in the quarter, up 11 percent. ... ICIS Event Brief of Q3 2006 Genzyme Corporation Earnings Conference Call -... - Oct 1, 2006 Cerezyme, Fabrazyme, Aldurazyme, Thymoglobulin, the Sepra products, Thyrogen, all produced pretty much the growth rates and results that GENZ [hasn't] seen ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Genzyme's 2004: Strong Sales, Growth Provided 'Stellar' Year - Jan 13, 2005 Sales of the Fabry's disease product Fabrazyme rose to $64 million in the fourth quarter and $209 million for the year. Moving forward, Genzyme expects to ... BioWorld Online - BioWorld Online Fosrenol's Threat To Renagel May Be Leveling Off: Report - Apr 18, 2005 One cloud over Genzyme remains in the form of Fabrazyme (agalsidase beta) competition overseas from Transkaryotic Therapies Inc.'s Replagal (agalsidase ... BioWorld Online - BioWorld Online A Call for Fairness in Formulary Decisions - Jan 9, 2006 Some of these drugs (eg, Fabrazyme) have not been convincingly shown to affect clinically important outcomes, 8 and others that do affect clinically ... Archives of Internal Medicine Event Brief of Q4 2004 Genzyme Corporation Earnings Conference Call -... - Feb 17, 2005 Fabrazyme showed the effect of the first full year of revenue in the US as ... Fabrazyme revenue is expected to increase due to continued penetration in the ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Biotech Stock Earnings Preview - Apr 8, 2008 Wall Street is looking for $301 million from the Gaucher disease drug Cerezyme, $118 million from Fabry disease treatment Fabrazyme, $68 million from the ... TheStreet.com - TheStreet.com (subscription) Profit soars tenfold at Genzyme Corp. - Oct 25, 2007 The medicines include Fabrazyme for Fabry disease and Aldurazyme for a genetic condition known as MPS1. Each drug costs an average $200000 a year per ... Boston Globe ОÑ?тановлен выпуÑ?к уникальных препаратов от редкого генетиче? - Jun 19, 2006 ОÑ?тановка производÑ?тва может вызвать дефицит лекарÑ?тв Fabrazyme ( агальзидаза-бета) и Cerezyme (имиглуцераза). ВируÑ? мог проникнуть в биореактор Ñ? ... ГÐ?ЗЕТÐ?.GZT.ru Biotech Preview: Genzyme, Biogen, Amgen, Celgene - Jan 14, 2008 Coming in at the top end of estimates, Fabry disease treatment Fabrazyme and Pompe disease treatment Myozyme generated sales of $114 million and $62 million ... TheStreet.com - TheStreet.com (subscription) Who lives, who dies?; The astronomical cost of treatment for rare … - Dec 15, 2005 Two approved drugs, Fabrazyme and Replagal, treat the disease by replacing that enzyme through bimonthly infusions. But Canada's Common Drug Review -- a ... Pay-Per-View - Daily Mercury - ProQuest Archiver Press Release: Genzyme Reports Financial Results for the First... - Apr 19, 2006 Sales of Fabrazyme(R) (agalsidase beta), Synvisc(R) (hylan G-F 20) and ... Fabrazyme growth will be driven by the continued accrual of new patients on ... Pay-Per-View - PR Newswire - HighBeam Research Sales of PCs, iPods bolster Apple - Apr 20, 2006 Revenue rose 16 percent to $730.8 million, but sales of Fabrazyme, a treatment for the rare genetic disorder Fabry disease; Synvisc, for osteoarthritis of ... Boston Globe Biotech Earnings: Second-Quarter Preview - Jul 8, 2008 ...for roughly $170 million to $173 million from Renagel/Renvela, $69 million from Myozyme, $309 million from Cerezyme and $122 million from Fabrazyme. ... TheStreet.com - TheStreet.com (subscription) Clinical benefit of enzyme replacement therapy in Fabry disease - Feb 22, 2006 ...rhGalA (agalsidase ; Fabrazyme ® , Genzyme, Cambridge, MA, USA) was administered intravenously at a dose of 1 mg/kg of body weight. ... Nature.com Biotech Earnings: Second-Quarter Preview - Jul 11, 2008 ...for roughly $170 million to $173 million from Renagel/Renvela, $69 million from Myozyme, $309 million from Cerezyme and $122 million from Fabrazyme. ... TheStreet.com - TheStreet.com (subscription) Amicus, Shire Team on Rare Gene R&D - Nov 8, 2007 Genzyme also reported $53.6 million in sales from Myozyme therapy for Pompe disease and $104.6 million in sales of Fabrazyme, a recombinant form of a human ... TheStreet.com - TheStreet.com (subscription) Rare can still end up in your chair: consider these three rare... - Jul 15, 2006 Fabrazyme (agalsidase beta) package insert. Cambridge, MA, 2004. 15. Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. ... Free with registration - Review of Optometry - AccessMyLibrary.com Eye On Stocks Eye On Stocks For Thursday, Feb. 17 - Feb 16, 2005 Cerezyme sales of $219 million were $12 million above our estimate and Fabrazyme sales of $64 million were $4 million above our view. ... Forbes Genzyme to Acquire Bone Care, Adding Complementary Therapy to … - May 4, 2005 In addition to Renagel, Genzyme developed and now markets Fabrazyme, an enzyme replacement therapy for Fabry disease, a degenerative disorder that can lead ... Wisbusiness.com Vaincre les maladies lysosomales: Forum - Apr 15, 2007 Pour mon homme après ses perf (fabrazyme aussi), non il n'est pas colérique mais il a froid, pas très faim..Pour ce qui est colérique, ça lui arrive parfois ... Association Vaincre les Maladies... US Stock-Index Futures Gain; Intel, Microsoft Rise (Correct) - Jan 12, 2005 The biotechnology company that sells drugs for rare genetic diseases said fourth- quarter revenue rose 23 percent, boosted by higher sales of its Fabrazyme ... Bloomberg Genentech sale could make big biotech ripples - Jul 21, 2008 Apart from Tanner's take, Genzyme has one of the biggest biotech businesses in the world, with products such as Cerazyme and Fabrazyme that contributed to ... Mass High Tech Genzyme wins approval for treatment of rare genetic disorder - Apr 28, 2006 Although Genzyme has not yet announced a price for the new drug, Myozyme, the company says it will cost as much as its related drugs, Cerezyme and Fabrazyme ... Boston Globe Genzyme Shares Too Cheap To Ignore: Report - Sep 14, 2006 ..."While emerging potential competition for Cerezyme/Fabrazyme will keep Genzyme's multiples below the group mean this year, we believe stock has upside," ... Forbes Genzyme's Gaucher disease pill promising in trial - May 16, 2007 Amicus is also developing oral versions of several other Genzyme drugs, including Fabrazyme, a treatment for the rare genetic disorder Fabry disease and ... Reuters Genzyme Boosts Second-Quarter Profit, Raises Forecast - Jul 25, 2007 Sales of Fabrazyme, which treats Fabry disease, rose 17 percent to $104.3 million. Medicines for rare ailments account for almost half of the Genzyme's ... Bloomberg Profits Top Estimates at Genzyme - Jul 12, 2006 For the second quarter, sales of the Fabry disease drug Fabrazyme were up 20% to $89 million, boosted by the number of new patients on the drug. ... TheStreet.com - TheStreet.com (subscription) Kidney Worries Hit Genzyme | Althea Chang News | Print Financial & … - Apr 21, 2005 Sales of Fabrazyme, Genzyme's enzyme replacement therapy for Fabry disease, rose 84% to $70 million. Genzyme has submitted proposed labeling changes to the ... TheStreet.com - TheStreet.com (subscription) Eye On Stocks Eye On Stocks For Friday, May 12 - May 11, 2006 ..."While emerging potential competition for Cerezyme and Fabrazyme will keep Genzyme's multiples below the group mean this year, we believe the current ... Forbes Genzyme Beats Estimates, Raises Outlook - Jul 25, 2007 Enzyme replacement therapy Fabrazyme saw sales increase 17%, to $104.3 million; sales of MPSI, or Hurler Syndrome, therapy Aldurazyme rose 24% to $29.1 ... TheStreet.com - TheStreet.com (subscription) Genzyme diarrhea drug may be blockbuster - Feb 22, 2006 He said he sees the drug following a similar growth trajectory as its drug Fabrazyme for Fabry disease, a condition which causes fats to build up in blood ... Reuters Genzyme expects 2007 profit to rise on drug sales - Jan 9, 2007 Fourth-quarter sales of Fabrazyme, the company's drug to treat Fabry disease, which causes blood fats to build up in blood vessels, rose 18 percent to $96 ... Reuters Big Pharma Boosted By Q1 Earnings - Apr 24, 2006 ..."We continue to expect near-term growth to be driven largely by Renagel (due to impact of DCOR and Medicare Part D), Fabrazyme, Synvisc and, ... Forbes Drugs stocks mixed; Altus, Amicus plunge - MarketWatch - Dec 20, 2007 ...not elicit as strong a response in Fabry patients as a rival drug marketed by Genzyme Corp. called Fabrazyme. Shares of Genzyme were up 3% at $74.99. MarketWatch Bright Spots Among Biotech, Drug Stocks - Jul 14, 2006 ..."We expect sales of [Renagel, Cerezyme and Fabrazyme] to remain strong, and we are positive on the potential for Myozyme, as well as several other ... Forbes Genzyme 'bullish' on future growth - Jan 9, 2008 Fabrazyme, a treatment for Fabry disease, increased 18 percent to $114 million. Genzyme's drugs for rare hereditary disorders treat illnesses caused by a ... Boston Globe Genzyme to begin $150m expansion of Allston plant - Sep 15, 2007 It produces several drugs to treat rare diseases: Cerezyme for Gaucher disease, Fabrazyme for Fabry disease, and Myozyme for Pompe disease. ... Boston Globe It costs how much? - May 6, 2007 Fabrazyme, a Genzyme drug for a similar rare disease, generated $359 million in revenue last year. But those numbers are dwarfed by the total spending on ... Boston Globe Press Release: Bayer Announces Upcoming Presentations of Campath(R … - Dec 5, 2008 Article: Genzyme Receives Approval to Market Fabrazyme(R) in Japan. PR Newswire; January 29, 2004 ; 700+ words ... ... side effects reported with Fabrazyme ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme Has Fourth-Quarter Loss; Sees Higher Sales - Feb 14, 2007 Sales of Fabrazyme for the rare Fabry disease are expected to reach $415 million to $425 million this year, up from $359 million in 2006. ... Bloomberg Shire Pharma to pay $1.6B for Transkaryotic - Apr 21, 2005 ...replacement therapy for Fabry disease, sells internationally but not in the United States, following a battle to compete here with Genzyme's Fabrazyme. ... Bizjournals.com Does enzyme replacement therapy improve symptoms of Fabry disease … - Aug 26, 2005 Recombinant -galactosidase A (Fabrazyme®, Genzyme, Cambridge, MA) 1 mg/kg was infused intravenously every 2 weeks. Clinical, electrocardiographic and ... Nature.com Acquisition signals shift from US market - Jun 3, 2005 Indeed, the US Food & Drug Administration (FDA) insists that Replagal should first be proved superior to rival Fabrazyme from Genzyme of Cambridge, ... Nature.com Complement inhibitors finally find orphan niches - Mar 29, 2006 With its Cerezyme (imiglucerase), Fabrazyme (agalsidase beta) and Aldurazyme (laronidase) treatments, all for ultra-orphan diseases, Genzyme of Cambridge, ... Nature.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |